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Collectins are characterized by a collagen-like sequence and a carbohydrate recognition domain and are members of the vertebrate
C-type lectin superfamily. Recently, “novel collectins”, diﬀerent from “classical collectins” consisting of mannan-binding lectin
(MBL) and surfactant proteins A and D (SP-A and SP-D), have been found by reverse genetics. These “novel collectins” consist of
collectin liver 1 (CL-L1), collectin kidney 1 (CL-K1), and collectin placenta 1 (CL-P1) and are encoded by three separate genes.
Experimental ﬁndings on human and animal collectins have shown that both novel collectins and classical collectins play an
important role in innate immunity. Based on our recent results and those of others, in this paper, we summarize the new biological
functions of these novel collectins in embryonic morphogenesis and development.
1.Introduction
Collectin is a C-type lectin conserved in animals from
amphioxus to mammals. This protein possesses two charac-
teristicstructures,acollagen-likedomainandacarbohydrate
recognition domain (CRD). Recently, human collectins have
been divided into two classes. The ﬁrst is comprised of three
“classical collectins”, one harboring a mannan-binding lectin
(MBL) [1], as well as two others, lung surfactant protein A
(SP-A) [2] and lung surfactant protein D (SP-D) [3]. The
second class is made up of three “novel collectins” consisting
of collectin liver 1 (CL-L1) [4], collectin kidney 1 (CL-K1)
[5], and collectin placenta 1 (CL-P1) [6]. MBL, an early
discovered serum lectin, speciﬁcally recognizes carbohydrate
moieties on microorganisms and is directly associated with
innate immunity or acts through complement activation or
opsonization via collectin receptors [7, 8]. Two surfactant
proteins, SP-A and SP-D, also seem to play some role in host
defence against various microbes [9, 10]. All three classical
collectins are known to act in innate immunity as ﬁrst-line
host defence molecules.
Recently, cDNAs encoding the three new human col-
lectins, CL-L1, CL-K1, and CL-P1, were cloned, and the
properties of the products of these cDNAs were elucidated.
Thesenewcollectinshavebeenclassiﬁedas“novel”andform
three separate groups that diﬀer from the earlier discovered
classical ones. In this paper, the biological characteristics of
these novel collectins will be presented.
2.Collectin Liver1andKidney 1(CL-L1,
COLEC10,andCL -K 1 ,COLEC11)
Our laboratory has cloned two cDNAs encoding these new
proteins by screening human EST databases [4]. Cap site
hunting was performed to determine the complete sequence,
and it was designated collectin liver 1 (CL-L1) since mRNA
of this collectin was ﬁrst found in liver [4]. Secondly, the
screening of the EST database using the amino acid sequence
of the hCL-L1 CRD region discovered an EST clone, which
appeared to encode the C-terminal region of a new human
collectin. We isolated full-length cDNA by 5 -RACE and2 Journal of Biomedicine and Biotechnology
cap site hunting using human kidney cDNA libraries [5].
This new human collectin from the kidney was termed
collectin kidney 1 (CL-K1). CL-L1 cDNA consists of a
nontranslated 75-nucleotide sequence at 5 prime followed
by 831 nucleotides corresponding to the full-length protein
and another nontranslated 759-nucleotide sequence with
an“AATAA” incomplete polyadenylation signal at 3 prime
[4]. The cDNA encoding CL-K1 had an open reading
frame of 1383bp, consistent with a sequence of 271 amino
acid residues [5]. The cDNA contains a 240-nucleotide
5 -nontranslated sequence, followed by 813 nucleotides
corresponding to the full protein, and a 330-nucleotide
3 -nontranslated sequence with an “AATAA” incomplete
polyadenylation signal. The amino acid sequences deduced
from the CL-L1 and CL-K1 cDNAs reveal that they have a
collectin structure consisting of an N-terminal region with
cysteine residues, a collagen-like region, a neck region, and
a CRD. However, no CL-L1 hydrophobic signal peptide
sequence was evident at the N-terminal region due to PSOLT
(prediction of protein sorting signals and localization sites in
amino acid sequences), thus N-terminal amino acid of the
matured protein was not identiﬁed. It indicated that CL-L1
was presumed to be an intracellular protein. On the other
hand,ahydrophobicityplotanalysisshowedthattheproduct
from CL-K1 cDNA contained a signal peptide consisting of
25 amino acids at its N-terminal end and a predicted mature
protein of 246 amino acids.
CL-L1 is a cytoplasmic-type collectin, whereas CL-K1 is
asecreted-typecollectin.Otherwise,theirgeneorganizations
are very similar (Figure 1). The sizes of the three exons
encodingthecollagen-likedomaininCL-L1andCL-K1were
72bp, 72bp, and 54bp, respectively. Their gene organization
and the phylogenetic tree obtained using the amino acid
sequence of the CRD indicated that these two genes evolved
similarly from the same ancestor of the collectin gene
[5]. Moreover, phylogenetic ﬁndings suggested that the
two collectins should be considered to have emerged from
a prototype collectin gene older than the classical type
collectins MBL, SP-A, and SP-D.
Northern blot analysis of CL-L1 showed two bands with
approximate lengths of 1.2 and 3.8kb, which were mainly
detected in human liver. The 1.2-kilobase mRNA was
considerably more abundant than the 3.8-kilobase form.
RT-PCR analyses also showed relatively high expression of
hCL-L1 mRNAs in liver, placenta, adrenal gland, lung, small
intestine, and prostate [4]. In the case of CL-K1, RT-PCR
analyses showed high levels of mRNA in human and murine
kidney, liver, fetal liver, small intestine, thymus, spinal
cord, placenta, adrenal gland, and pancreas [5, 11]. The
expressionpatternofCL-K1inmurinetissueswasconﬁrmed
by immunohistochemistry analysis [11].This ubiquitous
expression is similar to that of CL-L1 but diﬀerent from that
of SP-A, SP-D, and MBL.
Immunoblot analyses using human liver demonstrated
that CL-L1 was distributed to the cytoplasm, but not to the
microsole or nucleus, and that the relative molecular size of
the detected band corresponded to 40kDa under reducing
conditions.Immunoﬂuorescenceanalysesofhumanprimary
hepatocyte cells also detected CL-L1 in the cytoplasm. In
addition, in Chinese hamster ovary (CHO) cells transfected
withpcDNA3.1/Myc-HisAvectorcontaininghCL-L1cDNA,
CL-L1 also localized in the cytoplasm. Human and mouse
CL-L1 have a very unique C-terminal lysine cluster (Lys-
Lys-Lys-Lys), whose four consecutive lysine residues are
thought to act as a nuclear localization signal (NLS) in
yeast aminoacyl tRNA synthetases [12]. This lysine cluster
has also been observed in human cytoplasmic methionyl-
tRNA synthetase (MRS) at the C-terminal end [13]. It
is not known if the four lysine residues act as an NLS,
translocating CL-L1 to the nucleus. Analysis of the cellular
expression of CL-L1 protein is needed for characterizing
its biological functions. Furthermore, a functional analysis
should be performed to examine how the four lysine cluster
might act as an NLS. Kawai and our group demonstrated the
presence of murine CL-L1 and its mRNA in murine embryos
and amnion, visceral yolk sac, and liver [14]. We observed
that its mRNA expression increased with embryonic age and
peaked dramatically on day 12 [14]. CL-L1 may be involved
in embryonic development, but further investigations are
required to elucidate the biological function of human and
murine CL-L1. On the other hand, cellular localization of
CL-K1 was performed by coupling it to a myc-His tag in
CHO cells to create a fusion construct [5]. Immunostaining
analysis using antimyc antibody and BODIPY TR as a
speciﬁc Golgi marker and immunoblotting using an anti-
carboxyl terminal myc tag antibody and anti-CL-K1CRD
antibody revealed that CL-K1 is a secreted-type protein
since it was detected to a much greater extent in culture
medium than in cell lysates. The molecular size of CL-
K1, which was puriﬁed as mannan-binding fraction from
human serum and recombinant CL-K1 proteins without the
myc-His tag, was determined to be approximately 34kDa
by western blot analysis [5]. We also determined partial
amino acid sequences of native CL-K1 and recombinant
CL-K1 and these sequences are Gln26-Pro-Ala-Gly-Asp-
Asp-Ala32 and Lys119-Ala-Iso-Gly-Glu-Met-Asp-Asn-Gln-
Val-Ser-Gln-Leu-The-Ser-Glu-Leu-Lys137, respectively. In
addition, CL-K1 has other splicing variants with or without
two collagen exons. Immunoblotting using recombinant CL-
K1 proteins was performed and the complete size of CL-K1
with two collagen exons proved to be 34kDa. The small CL-
K1s were 30 and 28kDa for one with exon and one without
any exon, respectively.
The biosynthesis of a protein harboring a collagen
triple helix is very unique, and it is essential that endo-
plasmic-reticulum-resistant chaperone heat-shock protein
47 (Hsp47) be used. Hsp47 binds to the collagen-related
protein, which can correctly fold the triple-helical structure
and give its stable form. Koide and our group reported that
CL-L1 and CL-P1 are able to use this Hsp47 as a molecular
chaperone [15]. In contrast, we found that MBL-2, MARCO,
and adiponectin, which retain a collagen-related domain,
do not seem to use this Hsp47. The usage of Hsp47 as
a molecular chaperone is considered to be dependent on
the presence of the Hsp47-binding motif in the protein,
suggesting that CL-K1 has Hsp46-binding motif.
Sugar binding speciﬁcity was examined using recombi-
nant hCL-L1CRDs produced in E.coli [4]. TworecombinantJournal of Biomedicine and Biotechnology 3
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Figure 1: The gene organization of human collectins and a comparison of the rates of the homology among the individual domains of
human and murine collectins. In the gene organization schematic, the domain structure can be seen to consist of an intraplasmic domain,
a transmembrane domain, a coiled-coil domain, a cysteine-rich domain, a collagenous domain, a neck domain, and a CRD. Collectin
components are listed in the table as the N-terminal region, a collagen-like domain, a neck domain, a CRD, and the whole (domain).
hCL-L1 CRD fusion proteins, hCL-L1 CRD-histidine tag
fusion protein (hCL-L1-CRDhis) and hCL-L1 CRD-maltose
binding fusion protein (hCL-L1-CRDmal), were established.
Sugar-blot analyses demonstrated that the two recombinant
hCL-L1 CRDs possess Ca++-dependent binding activity
towards mannose. ELISA analyses using same sugar probes
indicated that hCL-L1 has the ability to bind to D-mannose,
L-fucose, and D-galactose > N-acetylglucosamine   N-
acetylgalactosamine. Kawai and our group reported that the
recombinant mCL-L1 CRD exhibited properties similar to
recombinanthCL-L1[14].Sugar-blotanalysesdemonstrated
that CL-K1 has the ability to bind to L-fucose, weakly to D-
mannose, but it could not bind to N-acetylgalactosamine,
N-acetylglucosamine, or D-glucose [5]. We observed that
CL-K1 Ca++ dependently bound to L-fucose-agarose, weakly
to mannan-agarose and N-acetylglucosamine-agarose, but
not at all to maltose-agarose or N-acetylgalactosamine-
agarose.Unexpectedly, MBL could bind maltose-agarose and
L-fucose-agarose,andboundevenmorestronglytomannan-
agarose and N-acetylglucosamine-agarose [16]. Monosac-
charide inhibition of CL-K1 binding to mannose-conjugated
BSA was strongest with L-fucose and D-mannose followed
by D-glucose and weakest by N-acetylglucosamine and D-
galactose [17]. The ﬁve amino acid residues of the CRD,
namely, the lectin frame, are responsible for its association
with calcium ions in the binding of carbohydrates [18,
19]. The two amino acid residues in the CRD of CL-K1
are Glu232 and Asn234 (Glu-Pro-Asn)a si nt h a to fM B L .
The lectin frame further supports its binding speciﬁcity for
D-mannose, D-glucose, L-fucose and N-acetylglucosamine.
However, CL-K1 binds strongly to L-fucose, but hardly to
N-acetylglucosamine. We found that the four cysteines and
other14aminoacidresidues,includingGluandAsnofCRD,
were conserved among the three classical collectins [4]. The
cysteines in the CRD are not for oligomerization, which is
through those at the N-terminal of the collagen domain in
MBL. However, the basic frame of MBL had two amino
acid residues, Tyr231 and Asn233, which were substituted by
Phe225 and Lys227 in the case of CL-K1. These substitutions
might change the ability of the latter to bind to the N-
acetylglucosamine [5].
Keshi and our group investigated the characteristics of
recombinant CL-K1 binding to LPS and LTA from microbes
using lectin blotting on ELISA plates [5]. We observed that
CL-K1 and MBL could bind to LPS from Escherichia coli
EH100 (Ra mutant) and Escherichia coli F583 (Rd mutant)
a n dt om a n n a nf r o mSaccharomyces cerevisiae. CL-K1 also
bound to LPS from Klebsiella pneumoniae, similar to the4 Journal of Biomedicine and Biotechnology
binding of MBL to LPS of Salmonella minnesota and to LTA
of Staphylococcus aureus and Streptococcus pyogenes/sanguis.
We demonstrated that the binding of CL-K1 to LPS or LTA
was very weak compared with that of MBL seen on lectin
blotting. It is known that MBL recognizes carbohydrates on
microbes via the CRD and can bind to them and activate the
complement pathway [20–23]. These results all suggest that
CL-K1 and CL-L1 might play some role in innate immunity.
Crystallography analysis and a point mutation study on
the binding of MBL and MASP showed that the MASP-
binding site was located in the collagen-like domain in
MBL [24, 25]. Wallis et al. demonstrated that incorporation
of the MASP-binding site (Hyp-Gly-Lys-Xaa-Gly-Pro) into
SP-A, which does not activate a complement pathway,
can activate complement pathway. However, its activation
was uncontrolled and observed even in the absence of a
carbohydrate molecule. The introduction of the additional
amino acid sequence into the mutated SP-A might be needed
for the physiological capacity for complement activation
and deactivation. These results also revealed that CL-K1
like MBL, ﬁcolin, and C1q possesses an MASP-binding site
containing a protease-binding motif. After this experiment,
Holmskov et al. demonstrated that CL-K1 could activate the
complement pathway using recombinant CL-K1, and they
conﬁrmed its antimicrobial activity and tissue localization
[17]. Furthermore, their ﬁndings with a small number of
people showed that the blood concentration of CL-K1 was
about 2 microgram/mL. We supposed several possibilities in
the diﬀerences of ethnicity, sample sizes, and methods why
its concentration was lower than that of our ELISA.
More recently, a surprising report has been published
showed that the deletion of CL-K1 due to a gene mutation
causes physical anomalies in humans [26]. This disease is a
rare autosomal recessive genetic disorder which is designated
as3MCsyndrome(Mingarelli-Malpuech-Michels-Carnevale
syndromes). It is characterized by high arched eyebrows,
ptosis, cleft palate, cleft lip, down-turned mouth, cognitive
impairment, growth deﬁciency, and an insuﬃciency of
craniosynostosis. Another related gene is the MASP-3 gene,
which has the same mutation and deletion as the CL-K1
gene [26, 27]. Both genes were associated with a complement
activation pathway so that mutations in these two genes
might cause a hereditary disease. Yoshizaki and our group
established a system for detecting CL-K1 in blood using
several types of antibodies [28]. ELISA analysis of over 200
people showed that human blood concentration of CL-K1
was about 0.34 ± 0.13 micrograms/mL, lower than that of
MBL. These two collectins are produced in liver, but their
levels of expression have no correlation with each other.
The concentration of CL-K1 is maintained at a low level
without ﬂuctuation, and its concentration is not dependent
on gender or age. The ELISA system will be useful for
elucidating the physiological and pathophysiological role of
CL-K1 as well as in detecting the 3MC syndrome.
3.CollectinPlacenta1(CL-P1,COLEC12)
Screening of the EST database using tblastn of the NCBI
revealedahumancDNAclonefromahumanplacentacDNA
librarythatencodedacollectin-likeprotein.Thisproteinwas
also named collectin placenta 1 (CL-P1) since mRNA of this
protein was abundant in placenta [6]. Its cDNA sequence
revealed that CL-P1 has an open reading frame of 2226 base
pairs encoding a sequence of 742 amino acids. We found
thatthededucedaminoacidsequencerepresentedacollectin
protein containing a collagenous region and a CRD. In addi-
tion, it harbored an intracytoplasmic domain, transmem-
brane domain, and coiled-coil domains from the N-terminal
end of its open reading frame. CL-P1 cDNA transfection
resulted in immunoﬂuorescent staining of the membranes
of the transfected CHO cells using anti-myc tag and anti-
CRD antibodies [6]. Moreover, CL-P1 was also detected
on the surface of human umbilical vein endothelial cells
(HUVEC) using anti-CRD antibody. These results strongly
suggestthatCL-P1islocalizedonthecellmembraneasatype
II transmembrane protein. Results of immunocytochemistry
demonstratedtheexpressionoftheCL-P1proteininvascular
endothelium and artery in murine and human [17, 29]. Its
cellular expression in HUVEC and human umbilical artery
endothelial cells (HUAEC) was shown by ﬂow cytometry.
However, THP-1, U937, and HL-60 treated with LPS, as
well as macrophages showed no expression of this protein.
SDS-PAGE and immunoblotting under reducing conditions
revealed that CL-P1 had an approximate molecular mass
of 140kDa in CL-P1-cDNA-transfected CHO cells (CHO-
CL-P1), HUVEC, and placental membrane extracts and that
it might possess several N-glycosylation sites in its coiled-
coil region and CRD. This was conﬁrmed by deglycosylation
treatment and in vitro translation. The higher molecular
weight of the CL-P1 band under nonreducing conditions
indicated that it was an oligomeric structure due to its
collagen-like and coiled-coil helical domains.
ThedomainstructureofCL-P1seemedtobeverysimilar
to that of the scavenger receptor AI (SR-AI) judging from
its predicted structural characteristics. We noted that the
SR-cysteine-rich domain in SR-A was replaced by the CRD
of CL-P1. To elucidate the function of CL-P1, the binding
activity in CHO ldlA7 cells expressing CL-P1 and SR-BI was
investigated using modiﬁed LDL. Results showed that CHO-
CL-P1 cells bound to OxLDL but not to Ac-LDL or LDL,
although CHO-SR-BI cells could bind to all LDLs (OxLDL,
AcLDL, and LDL), while the control CHO ldlA7 cells did
not bind to any of them [6]. The binding of OxLDL to
CHO-CL-P1 cells was inhibited by the negative polycharged
substances poly-I/G and dextran sulfate but not by LDL or
AcLDL. Taken together, these results indicated that CL-P1
plays a role as a scavenger receptor. A previous study revealed
that E. coli and S. aureus,b u tn o tSaccharomyces cerevisiae
(yeast), could bind to SR-A and MARCO [30]. However,
CHO cells expressing CL-P1 bound and phagocytosed yeast
as well as E. coli and S. aureus. Recently, SR-AI knockout
mice were shown to have an increased mortality from HSV
and Listeria infections [31, 32]. These results indicate that
scavengerreceptorsincludingCL-P1mayplayaroleininnate
immunity, although CL-P1 is not a soluble-type collectin. In
vascular spaces, CL-P1 might not only control the expansion
of bacteria and yeasts but also regulate the amount of
modiﬁed LDLs. Collagen-like domains, which have theJournal of Biomedicine and Biotechnology 5
highest homology between amino acid sequences of human
and murine CL-P1 and harbor positively charged islands,
may play an important role in its binding to the negatively
charged substances. SR-A, another scavenger receptor with
a collagen-like domain, also maintains a strong homology
between these charged sites of humans and mice. Mutation
analysis showed that the positively charged islands formed
binding sites for many ligands [33]. Jang and our group
demonstratedtheexpressionofCL-P1inhumanandmurine
vascular endothelium by immunohistochemistry and real-
time PCR analysis [29]. We characterized CL-P1-dependent
phagocytosis in CL-P1-transfected cells as well as in human
vascular endothelial cells. The use of small interfering RNAs
of CL-P1 or other scavenger receptors showed that CL-P1
predominantly mediated phagocytosis of yeast in human
vascular endothelium. CL-P1-dependent phagocytosis of
fungi was also observed under culture conditions using
serum and the eﬃciency of its phagocytosis in the culture
medium increased several-fold when the serum was added.
These results indicate that this phenomenon might occur
under physiological conditions.
Yoshida et al. showed that CL-P1 was expressed in nurse-
like cells and that recombinant CL-P1 fusion protein could
bind to N-acetylgalactosamine. They demonstrated that this
interaction was inhibited by N-acetylgalactosamine, T anti-
gen(galactose-β(1-3)(N-acetylgalactosamine-αSer/Thr),and
Tn antigen (N-acetylgalactosamine-α)1-O)Ser/Thr) [34].
Elolaetal.reportedthatCL-P1selectivelyboundtothesugar
moiety designated Lewisx (Lex)[ 35], which is also known
as stage speciﬁc antigen-1 (SSEA-1) having the structure of
galactose-β(1-4)-fucose-α(1-3)-N-acetylglucosamine. They
suggested that it might be expressed on glycoconjugates in
human polymorphonuclear granulocytes (PMN) as well as
in various tumors such as breast carcinoma, colon carci-
noma, and Hodgkin’s lymphoma. The glycan binding of CL-
P1anditsdistributiononvascularendothelialcellssuggested
that it might play a role in the binding of other cell adhe-
sion molecules to the selectin in mediating the leukocyte-
endothelial cell interaction. In addition, the Lex antigen is
present on various tumors and could mediate the adhesion
of cancer cells to vascular endothelium through CL-P1. This
interaction might be used to prevent tumor metastasis. Very
recently, results of aﬃnity chromatography on immobilized
CL-P1 and mass spectrometry-based proteomics demon-
strated that CL-P1 in vascular endothelial cells can bind
and endocytose neutrophil granule glycoproteins [36]. These
glycoproteins possess a multiclustered terminal Lex group
on a heterogenous mixture of branched glycans containing
partially poly-N-acetyllactosamine residues. These results
suggest that in vascular spaces, CL-P1 can act as a scav-
enger receptor in the clearance of glycoproteins released
from neutrophils at sites of inﬂammation both locally and
systemically.
CL-P1 was found to have a role in the scavenging of
amyloidinAlzheimer’sdisease(AD)byNakamuraetal.[37],
and the same group demonstrated that the expression of CL-
P1 on amyloid-positive astrocytes and vascular endothelial
cells was increased in a transgenic mouse AD model. A
similarCL-P1expressionwasobservedinADpatients.These
results suggest that CL-P1 might be involved in the clearance
of amyloid molecules. Another study carried out haplotype
analysis of the human CL-P1 gene of ten Japanese volunteers
[38]. Of the six SNPs found (one in the 5 -upstream region,
two in intron 2, one in exon 5, and two in exon 6), the two
in exon 6 caused amino acid substitutions. These haplotype
ﬁndings may be useful in studying disease associations.
Koyama and our group recently demonstrated the
induction of CL-P1 under in vivo and in vitro conditions
[39]. Hypoxia/reoxygenation stimulation induced CL-P1
mRNA and protein expression in HUVEC. Furthermore,
the exposure of rat carotid artery to ischemic/reperfusion
caused the upregulation of CL-P1 mRNA and protein, which
peakedat72hoursandat7daysaftertreatment,respectively.
The inducible expression of CL-P1 in vitro and in vivo
due to oxidative stress is implicated in the development of
endothelialdysfunctionandchronicactivationleadingtothe
pathogenesis of atherosclerosis. Kim and our group carried
out a promoter analysis using the 5  ﬂanking region of the
CL-P1 gene [40]. We found that this gene is mainly regulated
by three Sp1 (speciﬁcity protein-1) in the human CL-P1
proximal promoter and is a basic transcriptional factor. The
third Sp1-binding site is controlled through some other
factor, but not by an Sp1 protein, as observed with hydrogen
peroxide treatment.
Very recently, Fukuda and our group described surpris-
ing ﬁndings in zebraﬁsh [41]. We cloned the cDNA of a
zebraﬁsh CL-P1 (zCL-P1) which has 51% identity to human
CL-P1 in its amino acid sequence. The mRNA expression
of zCL-P1 was ﬁrst observed 6 hours postfertilization (hpf),
peaked at 24 hpf, and then decreased. The knockdown
analysis of zCL-P1 demonstrated that the zebraﬁsh embryos
had severe morphological abnormalities such as short body
length and defects in the dorsal aorta. The abnormalities
were rescued by the injection of zCL-P1 or zVEGF mRNA.
These results suggest a role for zCL-P1 in vasculogenesis
and development during the early embryogenic stage of
bony ﬁsh. Furthermore, in an in vitro study, it was revealed
that cells transfected with the zCL-P1 gene could bind and
endocytose modiﬁed LDL as well as microbes indicating
that zCL-P1 plays a role in innate immunity as does human
CL-P1. In addition, CL-P1 gene has high homology among
humans, mice, and bony ﬁsh, especially in the intraplasmic
region and collagen-like domain. The intraplasmic region
containing the endocytosis motif, and collagen-like region
has positively charged sites, suggesting that both regions
might be important in signal transduction for development
and for the scavenging functions of innate immunity.
4. The Biological Signiﬁcanceof
CollectinGeneEvolution
Phylogenetic relationships among amino acid sequences of
CRDs of various animal collectins have been demonstrated
[5] in a presentation of the six classes of the collectin family:
(1) the MBL group consisting of MBL, MBL-A, and MBL-
C; (2) the SP-A group; (3) the SP-D group made up of SP-
D, bovine CL-43, CL-46, and conglutinin; (4) the CL-P16 Journal of Biomedicine and Biotechnology
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Figure 2: A schematic of the gene evolution of collectin and complement 1q (C1q). The extraordinary numbers of the two genes in
amphioxus show that this life form has undergone enormous evolutionary changes since its emergence.
Table 1: Characteristics of classical collectin and novel collectin.
Classical collectin Novel collectin
MBL SP-A SP-D CL-L1 CL-K1 CL-P1
Chromosomal
location
human
10q11.2 10q22.3 10q22.2-
q23.1 8q23-q24.1 2p25.3 18pter-p11.3
mouse MBL-A:14
MBL-C:19 14 14 15 12 18
HUGO
COLEC no. 14 7 1 0 1 1 1 2
Localization Secreted Secreted Secreted Cytoplasmic Secreted Membrane
Tissue expression Liver Lung Lung Ubiquitous Ubiquitous Vascular
endothelium
Sugar-binding
speciﬁcities
GlcNAc > Fuc,
Man
ManNAc > Fuc,
Mal
Mal > Man,
Glc
Man, Fuc,
Gal Fuc > Man Gal, GalNAc, Lex
Lectin frame Y-N-EPN-E- Y-N-EPA-E Y-N-EPN-E Y-N-EPS-E- F-K-EPN-E Y-N-QPD-E
Binding activity Strong Strong Strong Weak Weak Weak
Biological activities Innate
immunity
Innate
immunity
Innate
immunity
homeostasis
of surfactant
Unknown
Innate immunity?
embryogenesis?
structuraldevelopment?
Innate immunity
scavenger receptor
group;(5)theCL-L1group;(6)theCL-K1group.Allhuman
gene names have been ﬁxed by HUGO (Human Genome
Organization). We have designated the novel collectin genes
as COLEC10 of the CL-L1 group, COLEC11 of the CL-K1
group, and COLEC12 of the CL-P1 group according to the
order of their discovery.
Very recently, the entire genomes of amphioxus and
urochordates have revealed that amphioxus have 66 collectin
modelgenesandurochordateshave9genes,whereashumans
retain only 6 [42, 43]. Most primitive-type collectins can be
observed in sea urchin. Screening of the entire genome was
carried out using several ﬁsh. Fugu and medaka ﬁsh were
found to have 4 collectin genes, while zebraﬁsh has no CL-L1
gene. CL-L1, SP-A, and SP-D genes emerged during or after
the evolution in bony ﬁsh. An analysis of chicken collectin
genes showed that the three novel collectin genes CL-L1, CL-
K1, and CL-P1 were conserved [44]. These results indicate
that the evolution of collectin genes has occurred several
t i m e s .T h eﬁ r s to c c u r r e n c ew a sw h e na m p h i o x u se v o l v e d
from sea urchin, the second was when ﬁsh evolved from
urochordates, and the third was when mammals evolved
from ﬁsh (Figure 2). The ﬁgure demonstrates the numbers
of collectin and complement 1q (C1q) at several stages of
animal evolution. Ancestors such as the sea urchin might
ﬁrst use lectin for complement activation, whereas more
advanced animals are able to use MBL, ﬁcolin, and CL-
K1 for the same activation. Finally, vertebrates can use not
only the lectin pathway and these collectins but also C1qJournal of Biomedicine and Biotechnology 7
and immunoglobulin in the classical pathway. The MASP
gene is associated with the collectin gene and both evolved
similarly, which may account for their similar involvement
in the complement activation pathway. Since both genes
have acquired an important role in vital homeostasis and
embryonic development during gene evolution, they need to
be conserved very strictly, and gene diversiﬁcations caused
by a mutation, deletion, or insertion must be rejected. The
classical collectin genes MBL, SP-A, and SP-D, which play a
role in innate immunity, have all acquired genetic changes
that ﬁt their circumstances. On the other hand, CL-P1 is a
membrane-type collectin as well as scavenger receptor, and
its orthologue genes are highly conserved among various
animals. These ﬁndings indicate that the genes essential for
homeostasis must be conserved tightly if they are to survive
evolutionary pressure (Figure 1).
5. Conclusion
In this review, the possible biological functions and charac-
teristics of the novel collectins, CL-L1, CL-K1, and CL-P1,
were summarized (Table 1). These new collectins function as
innate immune molecules similar to the classical collectins
based on in vitro studies. In addition, as seen in vivo, they
might mediate development and vascular formation in bony
ﬁsh, mice, and humans. Recently, it has been shown that
CL-K1 is essential for developmental process during human
embryogenesis. CL-L1 expressed in cytoplasm is a unique
collectin with interesting biological functions. CL-K1 is a
secreted protein, although it is very similar to CL-L1 with
respect to its amino acid sequence, genomic organization,
andgenedevelopment.Thethirdcollectin,CL-P1,wasfound
to behave like a scavenger receptor in a cell expression
study. Preliminary results suggest that CL-P1 might have
an important role in development as well as in vascular
homeostasis. At present, we are just at the beginning of
collectin research and many questions may be resolved in the
near future.
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